A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function

NCT07426380 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Disease
Renal Insufficiency Chronic
Kidney Failure, Chronic
Renal Impairment
Renal Insufficiency
End Stage Kidney Disease

Interventions

DRUG: LY3841136

Sponsor

Eli Lilly and Company